# Q'Apel Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/q-apel-medical

- Industry: Medical Devices & Equipment
- Headquarters: Fremont, US
- Website: www.qapelmedical.com
- Total disclosed funding: $22M
- Latest round: Series C (Feb 5, 2021)
- Investors on record: 3

## About

Based in the US, Q'Apel Medical Inc. innovates in developing advanced neurological catheter systems aimed at enhancing stroke care and neurovascular interventions.Founded in 2016 and headquartered in Fremont, US, Q'Apel Medical Inc. specializes in creating products for neurovascular interventions. The company has engaged in two deals, with the most recent being a Series C funding round in February 2021 where it raised USD 22.00 mn from investors including RC Capital, Research Corporation Technologies, and Soleus Capital Management. The current CEO, Nelson Nelson, oversees the company's operations as it focuses on expanding its reach in the neurovascular market.Q’Apel Medical specializes in developing innovative neurological catheter systems tailored for neurovascular interventions, particularly in stroke care. Their primary products include the Walrus Balloon Guide Catheter, the Armadillo SelectFlex™ Neurovascular Access System, and the Zebra Advanced Aspiration System. These systems are designed to navigate complex neurovasculature, facilitating therapeutic thrombectomy and addressing cerebral aneurysms. The company's offerings are primarily utilized in the United States, Europe, and other regions addressing stroke-related healthcare challenges, serving hospitals, surgical centers, and neurovascular clinics.Q’Apel Medical’s revenue model relies on direct sales to healthcare institutions and neurovascular specialists, operating a business-to-business (B2B) model. Their framework consists of selling individual catheter systems and related devices under contractual agreements with hospitals and clinics, which may include tailored agreements and volume-based pricing. The Walrus, Armadillo, and Zebra systems are central to their neurovascular access and intervention solutions.Following the Series C funding of USD 22.00 mn raised in February 2021, Q'Apel Medical Inc. plans to enhance its manufacturing capabilities, increase its workforce, and broaden its product portfolio. The company is also pursuing CE certification to facilitate its entry into the European market within the year. Additionally, the funding will support the introduction of upcoming new products, specifically designed to meet the evolving needs of the neurovascular field.

## Funding rounds

- Series C, Feb 5, 2021, $22M — RC Capital, Research Corporation Technologies, Soleus Capital

## Investors

- RC Capital (https://capitalatlas.ai/funds/rc-capital) — Series C
- Research Corporation Technologies (https://capitalatlas.ai/funds/research-corporation-technologies) — Series C
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series C